申请人:Novo Nordisk A/S
公开号:US11186595B2
公开(公告)日:2021-11-30
This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I′), which is: R1′-X′—R2′, in which either the moeities R1′ or R2′ or X′ carry a drug that is covalently attached to the diboron compound.
本发明涉及对葡萄糖敏感的白蛋白结合型二硼共轭物。更具体地说,本发明提供了新型二硼化合物,特别是二硼酸酯或二硼氧化合物,可作为合成二硼共轭物的中间化合物。二硼化合物的特征为式 (I),即R1-X-R2,其中 "X "是单原子到多原子连接体,其中 R1 和 R2(可以相同或不同)各自代表式(11a)或(IIb)的基团 还描述了由通式(I′)表示的二硼共轭物,通式(I′)为R1′-X′-R2′,其中R1′或R2′或X′中的任一分子带有共价连接到二硼化合物上的药物。